RGNX News and Press, REGENXBIO Inc. From 02/07/24

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial PR Newswire Completed enrollment in cohort 2 of the Phase I/II AFFINITY DUCHENNE ® trial of RGX-202, a potential one-time AAV Therapeutic f...

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 PR Newswire Pivotal topline results from the CAMPSIITE ® trial of RGX-121 for the treatment of MPS II to be presented Conference call Wednesday, February 7, 4:30 p.m. ET ...

2024-01-30 09:20:23 ET Summary AbbVie Inc.'s revenues have fallen in 2023 due to the expiration of patents for its best-selling drug Humira, but the decline has not been as severe as expected. AbbVie's share price has grown by 11% in the past six months and over 110% in the past f...

2024-01-21 18:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery PR Newswire A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among ant...

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting PR Newswire ROCKVILLE, Md. , Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE ® trial of suprachor...

2024-01-08 10:00:05 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit PR Newswire ROCKVILLE, Md. , Jan. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. District Court for th...

2023-12-24 08:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial PR Newswire First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On...